We are live on ! Find out more

CRON

Cronos Group

CRON

Market cap $1.19B

3.23 USD

+0.09

2.87%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

3.24

+0.01

0.31%

1 day

2.87%

5 days

-0.31%

1 month

2.87%

3 months

22.81%

6 months

27.17%

Year to date

19.63%

1 year

26.67%

5 years

-44.6%

10 years

-57.61%

About: Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.

Employees: 610

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 34.8%

Neutral 47.8%

Negative 17.4%

Zacks Investment Research

Are Medical Stocks Lagging Cronos Group (CRON) This Year?

Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Cronos Group (CRON) This Year?

Cronos' brand Spinach® Expands its Best-Selling Lineups of Edibles and Vapes

TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is expanding its lineup of edible multipacks with the SOURZ by Spinach® Blue Raspberry Lemonade Fully Blasted multipack, featuring its first live resin gummy. This month the brand will also launch new flavors in its best-selling lineup of vape cartridges, Strawberry Banana and Sweet Citrus Punch.

MarijuanaStocks

The Best Way Marijuana Stock Investing Can Work For You

As the cannabis industry continues to grow worldwide, there is a strong focus on the future. Many new changes are occurring throughout the sector—many of these impact businesses, investors, and potentially the end consumer. For marijuana stock investors, the new Schedule 3 bill for cannabis is soon to take effect. This will change how businesses operate, and some will have to pivot quickly.

The Best Way Marijuana Stock Investing Can Work For You

Zacks Investment Research

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

Zacks Investment Research

Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock

Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock

Marijuana reform is emerging as a midterm elections issue on both sides of the aisle

With November's pivotal midterm elections fast approaching, cannabis reform is emerging as an issue. Two states, Massachusetts and Idaho, will vote on ballot initiatives regarding legalization, and in several others, including Kansas and Iowa, gubernatorial candidates are debating cannabis matters.

Marijuana reform is emerging as a midterm elections issue on both sides of the aisle

Cronos Group: This Cannabis Name Isn't Reliant On U.S. Legalization Efforts

Cronos delivered a Q2 2026 earnings report that met bullish investor expectations. Strong quarterly performance reinforces the investment thesis for CRON's growth trajectory. Management execution and financial results support a positive outlook for CRON.

Cronos Group: This Cannabis Name Isn't Reliant On U.S. Legalization Efforts

Cronos: Strong Quarter, And The Outlook For The Future Is Positive Thanks To M&A

Cronos Group Inc. is rapidly expanding internationally, leveraging European legalization momentum and the CanAdelaar acquisition to become a major European cannabis player. Q2 results showed 58% YoY revenue growth to $53M, with margins benefiting from favorable sales mix and stable operating expenses. CRON maintains a robust balance sheet with nearly $800M in cash and short-term investments versus $56M in current liabilities, supporting buybacks and future M&A.

Cronos: Strong Quarter, And The Outlook For The Future Is Positive Thanks To M&A

Cronos Group Inc. (CRON:CA) Q2 2026 Earnings Call Transcript

Cronos Group Inc. (CRON:CA) Q2 2026 Earnings Call Transcript

Cronos Group Inc. (CRON:CA) Q2 2026 Earnings Call Transcript

Cronos Group Q2 Earnings Call Highlights

Cronos Group NASDAQ: CRON reported record second-quarter net revenue, gross profit and adjusted EBITDA for 2026, supported by growth in Israel, Canada and other international markets, including Germany.

Cronos Group Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™